Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Veronica A Guerra, MD, Yan Yuanqing, PhD, Joanne Hsu, BS, Feng Wang, PhD, Mansour Alfayez, MD, Kiyomi Morita, MD, Xingzhi Song, PhD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Guillermo Montalban Bravo, MD, Jianhua Zhang, PhD, Latasha Little, BS, Curtis Gumbs, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 458.

https://doi.org/10.1182/blood-2019-127498

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Neelam Mistry, MD, Diana Abbott, PhD, Japera Walker Wilkison, MA, Ajay Major, MDMBA, Brad M. Haverkos, MDMPH,MS, Manali Kamdar, MD

Blood (2019) 134 (Supplement_1): 4126.

https://doi.org/10.1182/blood-2019-129208

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy

Bruno Kosa Lino Duarte, MD, Marcos Paulo Colella, MD MSc, Fernando Vieira Pericole Souza, MD PhD, Gabriela G Yamaguti-Hayakawa, MD, Jose Francisco Comenalli Marques, Jr., MD PhD, Afonso Celso Vigorito, MD PhD, Erich Vinicius De Paula, MD PhD, Margareth C Ozelo, MD PhD

Blood (2018) 132 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2018-99-119884

Published: 2018

Journal Articles

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Maeve A O'Reilly, MB, Dinisha Govender, Ajay Vora, MD, Sujith Samarasinghe, Asim Khwaja, Victoria Grandage, Anupama Rao, Phil Ancliff, Danny Cheng, Ben Carpenter, Stephen Daw, David O'Connor, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 102.

https://doi.org/10.1182/blood.V130.Suppl_1.102.102

Published: 2017

Journal Articles

Synergistic Activity of Lysine Deacetylase Inhibitors and Microtubule-Targeting Agents in AML

James M Bogenberger, PhD, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben Mesa, MD FACP, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 3948.

https://doi.org/10.1182/blood.V128.22.3948.3948

Published: 2016

Journal Articles

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Vaibhav Agrawal, MD, M.B.A., Diane T. Smelser, PhD, David J. Carey, PhD, Joseph J. Vadakara, MD, Sharif S. Khan, MD

Blood (2016) 128 (22): 5963.

https://doi.org/10.1182/blood.V128.22.5963.5963

Published: 2016

Journal Articles

A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia

Danny V Jeyaraju, Rose Hurren, Xiaoming Wang, Neil MacLean, Marcela Gronda, Craig T Jordan, PhD, Mark D. Minden, MD PhD, Guri Giaever, Aaron D. Schimmer, MD PhD

Blood (2015) 126 (23): 3682.

https://doi.org/10.1182/blood.V126.23.3682.3682

Published: 2015

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

Neutropenic Enterocolitis: Clinical Features and Outcomes

Delphine Lebon, MD, Emmanuel Canet, MD, Lucie Biard, MD, David Schnell, MD, Camille Roussel, Sophie Buyse, Benoit Schlemmer, MD PhD, Elie Azoulay, MD PhD

Blood (2014) 124 (21): 5984.

https://doi.org/10.1182/blood.V124.21.5984.5984

Published: 2014

Journal Articles

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Mitul Gandhi, MD, Andrew M Evens, DO, MSc, Timothy S. Fenske, MD, Paul Hamlin, MD, Bertrand Coiffier, MD, PhD, Andreas Engert, MD, Alison J. Moskowitz, MD, Nilanjan Ghosh, MD, PhD, Adam M. Petrich, MD, Jon Lomasney, M.D., Amy Chadburn, M.D., Gary S. Wood, MD, Katrin Salva, M.D., Steven M Trifilio, BS Pharm, Dennis W. Raisch, PhD, MS, RPh, Dennis West, PhD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2013) 122 (21): 4380.

https://doi.org/10.1182/blood.V122.21.4380.4380

Published: 2013

Journal Articles

Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia

Blood (2013) 122 (21): 618.

https://doi.org/10.1182/blood.V122.21.618.618

Published: 2013

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Alternative Splicing and Expression of Class II Tubulin Beta ( TUBB2B ) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Satu Koivula, MSc, Ping Chen, MSc, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Alejandra Cervera, MSc student, Jan Delabie, Harald Holte, Jr., MD, PhD, Sampsa Hautaniemi, Sirpa Leppä

Blood (2012) 120 (21): 1557.

https://doi.org/10.1182/blood.V120.21.1557.1557

Published: 2012

Journal Articles

Optimized anti–tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule

Harald Ehrhardt, David Schrembs, Christian Moritz, Franziska Wachter, Subrata Haldar, Ulrike Graubner, Michaela Nathrath, Irmela Jeremias

Blood (2011) 118 (23): 6123–6131.

https://doi.org/10.1182/blood-2010-02-269811

Published: 2011

Includes: Supplemental data

Journal Articles

It's all in the timing

Linda J. Bendall

Blood (2011) 118 (23): 5983–5984.

https://doi.org/10.1182/blood-2011-09-381111

Published: 2011

Journal Articles

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BA, Amy Stejskal, MA, Ann Manziello, BS, Carla Morales, Daniel O. Persky, MD, Richard I Fisher, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2011) 118 (21): 2721.

https://doi.org/10.1182/blood.V118.21.2721.2721

Published: 2011

Journal Articles

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Thomas P. Miller, MD, Matthew S Squires, PhD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3930.

https://doi.org/10.1182/blood.V116.21.3930.3930

Published: 2010

Journal Articles

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Jonathan I Sive, MBChB, Georgina Buck, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 493.

https://doi.org/10.1182/blood.V116.21.493.493

Published: 2010

NARROW

Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs)

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study

Synergistic Activity of Lysine Deacetylase Inhibitors and Microtubule-Targeting Agents in AML

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

A Novel Isoflavone, ME-344, Targets the Cytoskeleton in Acute Myeloid Leukemia

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Neutropenic Enterocolitis: Clinical Features and Outcomes

Pancreatitis In Patients Treated With Brentuximab Vedotin: A Previously Unrecognized Serious Adverse Event

Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Alternative Splicing and Expression of Class II Tubulin Beta ( TUBB2B ) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Optimized anti–tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule

It's all in the timing

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only